Express Pharma
Home  »  Latest Updates  »  Boehringer Ingelheim, Lupin in agreement for type II diabetes

Boehringer Ingelheim, Lupin in agreement for type II diabetes

3

Lupin to market Empagliflozin under the brand name Gibtulio in India

Boehringer Ingelheim and Lupin announced strategic alliance to co-market Empagliflozin, a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor in India. According to the agreement, Lupin will market and sell Empagliflozin under a separate brand name Gibtulio. Boehringer Ingelheim will continue to sell Empagliflozin under the brand name Jardiance.

SGLT-2 Inhibitors are a novel class of drugs that were launched across the world in the last couple of years. Gibtulio and Jardiance tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus. They are available in 10 mg and 25 mg strength.

Announcing the launch, Shakti Chakraborty, Group President, India Region Formulations, Lupin said, “We are happy to expand our partnership with Boehringer Ingelheim to combat the growing menace of diabetes in India. I believe our entry into the fast growth SGLT-2 Inhibitors market with the launch of Gibtulio will further strengthen our overall diabetes portfolio.”

EP News Bureau

Comments are closed.